Cyclen-based lipidoids for mRNA delivery and immunotherapy

Area of Science:

• Biotechnology
• Materials Science
• Immunology

Background:

• Lipid nanoparticles (LNPs) are the preferred delivery platform for messenger RNA (mRNA) vaccines.
• 1,4,7,10-Tetraazacyclododecane (cyclen) is a promising ionizable head group for LNP development due to its protonation capability and modifiability.

Purpose of the Study:

• To design and synthesize novel cyclen-based lipidoids for efficient mRNA delivery.
• To evaluate the potential of these lipidoids as carriers for mRNA-based cancer immunotherapy.

Main Methods:

• Synthesis of cyclen-based lipidoids with varying linkages and hydrophobic tails.
• In vivo biodistribution studies in mice to assess mRNA delivery efficiency and targeting.
• Evaluation of antitumor immunotherapeutic potential using a subcutaneous EG.7-OVA tumor model.

Main Results:

• The lipidoid OEs-K showed high mRNA delivery efficiency and lymph node targeting.
• LNPs formulated with OEs-K promoted dendritic cell uptake, activated immune responses, and inhibited tumor growth.
• Hematological and histopathological analyses indicated no significant toxicity.

Conclusions:

• Cyclen-based lipidoids, particularly OEs-K, are effective carriers for mRNA delivery and cancer immunotherapy.
• OEs-K demonstrates potential for developing advanced mRNA vaccines with enhanced efficacy and safety.
• This research provides valuable insights for designing novel LNP materials for mRNA therapeutics.